Announcement • Oct 27
Motion For Case Conversion Approved for ViewRay, Inc. The US Bankruptcy Court gave an order granting the conversion of Chapter 11 reorganization of ViewRay, Inc. to liquidation under Chapter 7 on October 26, 2023. The debtor was facing losses in the business. Announcement • Sep 08
Nasdaq To Delist the Common Stock of ViewRay Nasdaq announced that it will delist the common stock of ViewRay, Inc. ViewRay, Inc.’s securities were suspended on July 26, 2023, and have not traded on Nasdaq since that time. Announcement • Jul 27
ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index ViewRay, Inc. has been dropped from Nasdaq Composite Index. Announcement • Jul 24
ViewRay Announces Commencement of Nasdaq Delisting Proceedings ViewRay, Inc. announced that on July 17, 2023 it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (‘Nasdaq’). Nasdaq has determined that due to the Company’s voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company’s ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company’s securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq’s determination. Trading of the company’s common stock will be suspended at the opening of business on July 26, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (‘SEC’), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Once the delisting from Nasdaq takes effect, the Company’s common stock is expected to begin trading on the over-the counter (‘OTC’) markets. On the OTC market, shares of the Company’s common stock, which previously traded on Nasdaq under the symbol ‘VRAY’, are expected to trade under the symbol ‘VRAYQ’. The transition to the OTC markets will not affect the Company’s intention to continue to operate in the normal course while in chapter 11. The Company will remain subject to the public reporting requirements of the SEC following the transfer. Announcement • Jul 23
ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board ViewRay, Inc. announced that on July 19, 2023, Mr. Sai Nanduri, a Senior Investment Analyst employed by Hudson Executive Capital LP, informed the Board of Directors of the Company that Mr. Nanduri was resigning from his position as an observer to the Board, effective immediately. Announcement • Jul 10
Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors On July 1, 2023, Susan Schnabel advised the Board of Directors (the “Board”) of ViewRay, Inc. (the “Company”) of her resignation from the Board, effective immediately. Ms. Schnabel’s resignation from the Board did not result from a disagreement with the Company or any of its officers or other directors on any matters relating to the operations, policies or practices of the Company. Announcement • Jul 03
ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market On June 26, 2023, ViewRay, Inc. received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC notifying the Company that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities maintain a minimum closing bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum closing bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company does not currently meet the minimum closing bid price requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Global Market at this time. The Notification Letter states that the Company has an automatic period of 180 calendar days to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to the expiration of the 180 calendar day period. If the Company does not achieve compliance with the minimum closing bid price requirement during the initial 180 calendar day period, the Company may be eligible for an additional 180 calendar day period if it applies to transfer the listing of the common stock to the Nasdaq Capital Market. To qualify, the Company must meet the continued listing requirement for the applicable market value of publicly held shares requirement and all other applicable initial listing standards for the Nasdaq Capital Market (except for the minimum bid price requirement) based on the Company’s most recent public filings and market information and provide written notice of its intention to cure the minimum bid price deficiency. If Nasdaq determines that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for such additional compliance period, Nasdaq will provide notice that the Company’s common stock will be subject to delisting. The Company intends to actively monitor the closing bid price of its common stock and will consider all available options to regain compliance with the listing requirements. The Company is committed to regaining compliance with the minimum closing bid price requirement prior to the expiration of all applicable compliance periods. Reported Earnings • May 12
First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.14 loss in 1Q 2022) First quarter 2023 results: US$0.16 loss per share (further deteriorated from US$0.14 loss in 1Q 2022). Revenue: US$22.5m (up 19% from 1Q 2022). Net loss: US$28.9m (loss widened 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • May 10
ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023 ViewRay, Inc. announced that they will report Q1, 2023 results After-Market on May 10, 2023 Reported Earnings • Mar 01
Full year 2022 earnings released: US$0.59 loss per share (vs US$0.67 loss in FY 2021) Full year 2022 results: US$0.59 loss per share (improved from US$0.67 loss in FY 2021). Revenue: US$102.2m (up 46% from FY 2021). Net loss: US$107.3m (loss narrowed 2.5% from FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 18% per year. Announcement • Feb 01
ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023 ViewRay, Inc. announced that they will report Q4, 2022 results After-Market on Feb 27, 2023 Announcement • Jan 22
ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors ViewRay, Inc. announced that it has reached an agreement with Hudson Executive Capital LP to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the ViewRay Board of Directors, effective as of January 20, 2023. The Company has also agreed that the Board will appoint Mr. Nanduri to fill any vacancy on the Board arising during the term of the agreement. Announcement • Jan 13
ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial ViewRay, Inc. announced that findings from the phase III randomized controlled MIRAGE trial (NCT04384770) were published on January 12 in JAMA Oncology. The MIRAGE trial compared MRI-guided and CT-guided stereotactic body radiation therapy (SBRT) for localized prostate cancer and found MRI-guided radiation therapy -- delivered with MRIdian -- to be superior in substantially reducing acute genitourinary (GU) and gastrointestinal (GI) toxicity. MRI-guided radiation was also associated with significantly better patient- reported quality of life metrics. The MIRAGE trial was led by Amar Kishan, M.D. (first author) and Michael L. Steinberg, M.D. (senior author) at the University of California, Los Angeles (UCLA). The study was independently designed, conducted, and analyzed exclusively by UCLA. In this trial, the investigator team randomized 156 patients to receive either MRI-guided SBRT or CT-guided SBRT. Acute grade >=2 GU toxicity rates were significantly lower with MRI guidance vs. CT guidance (24.4% in the MRI group vs. 43.4% in the CT group). Acute grade >=2 GI toxicity rates were also significantly lower with MRI guidance (0.0% in the MRI group vs. 10.5% in the CT group). On multivariate analysis, which controls for differences in the use of a rectal spacer, prostate size, and baseline urinary symptoms, the MRI-guided arm was associated with a 60% reduction in odds of grade >=2 GU toxicity. More notably, there were improvements in multiple patient-reported outcomes. Significantly more patients receiving CT- guided SBRT experienced large increases in urinary symptoms, as measured by a >15 points increase in International Prostate Symptom Score (IPSS) (6.8% in the MRI group vs. 19.4% in the CT group). Similarly, a significantly greater percentage of patients experienced a clinically notable decrease in bowel-related quality of life with CT-guided, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC-26) survey (25.0% in the MRI group vs. 50.0% in the CT group). Finally, though it is too early to conclude, as more than 2/3rds of men on the trial received hormonal therapy, exploratory analysis in men who did not receive hormonal therapy showed that patient-reported sexual-function scores (by EPIC-26) decreased more in men receiving CT-guided SBRT. To date, more than 27,000 patients have been treated with MRIdian. Currently, 56 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. Announcement • Jan 10
ViewRay, Inc. Announces CFO Changes Effective January 9, 2023, William P. “Bill” Burke has been appointed as Chief Financial Officer of ViewRay, Inc. He will succeed Zach Stassen in that capacity, who has stepped down after serving the company since April 2020. Mr. Burke will become a member of the company’s executive leadership team, reporting directly to Scott Drake, President and Chief Executive Officer and will lead all aspects of the company’s finance function including business planning and analysis, accounting, SEC reporting, internal audit, tax, treasury, and investor relations. Mr. Burke, 54, is a seasoned executive, who brings over 25 years of global financial and operational experience to ViewRay. He previously served as the Chief Financial Officer at Haemonetics, a global blood management solutions company, from August 2016 to April 2022 and stayed on in an advisory capacity through June 2022. From July 2014 to July 2016, Mr. Burke served as Chief Integration Officer and Vice President, Integration for Medtronic, plc, a global healthcare products company and was a member of its Executive Committee. In that role, he was responsible for ensuring the successful integration of Medtronic with Covidien plc, a global healthcare company, following its acquisition by Medtronic. Prior to joining Medtronic, Mr. Burke spent more than 20 years in finance and business development leadership roles at Covidien, including Chief Financial Officer for Covidien Europe based in Zurich, Vice President of Corporate Strategy and Portfolio Management and Vice President of Financial Planning and Analysis. Previously, he also held key positions within Tyco Healthcare, including the Financial Controller of Valleylab, Managing Director of the Covidien Group in Switzerland and International Controller. Since January 2022 Mr. Burke has served on the board of directors and as audit committee chair of MiroMatrix, a life sciences company and since July 2022, he has served on the board of directors and as audit committee chair of Axogen, a surgical solutions company. Mr. Burke began his career as an auditor with KPMG. He received a Bachelor of Science degree in Business Administration from Bryant College. Recent Insider Transactions • Nov 30
Insider recently bought €113k worth of stock On the 28th of November, Susan Schnabel bought around 25k shares on-market at roughly €4.52 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €1.5m more in shares than they have sold in the last 12 months. Reported Earnings • Nov 08
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.15 loss in 3Q 2021) Third quarter 2022 results: US$0.14 loss per share. Revenue: US$26.5m (up 38% from 3Q 2021). Net loss: US$26.1m (loss widened 3.3% from 3Q 2021). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Announcement • Nov 02
ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022 ViewRay, Inc. provides revenue guidance for the full year 2022. The Company updated its 2022 guidance. The Company is again raising the bottom end of its revenue guidance from $90 million to $94 million, and reiterated the top end of the range of $104 million. Announcement • Oct 29
ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial ViewRay, Inc. announced that the final primary endpoint results from the phase III randomized single-center MIRAGE trial were presented at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held October 23-26, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The trial was independently conducted by investigators at UCLA and compared MRIdian MRI- guided SBRT vs. CT-guided SBRT for localized prostate cancer. Final outcomes of the phase III randomized trial comparing acute grade >=2 genitourinary (GU) toxicity following MRIdian MRI-guided vs. CT-guided prostate SBRT determined that MRI-guidance significantly reduced acute grade >=2 GU and gastrointestinal (GI) toxicity. In the trial, 156 patients were randomized and received MRIdian MRI-guided SBRT or CT- guided SBRT (40 Gy in five fractions). Acute grade >=2 GU toxicity rates were significantly lower with MRI-guidance vs. CT-guidance (24.4% in the MRI group vs. 43.4% in the CT group). Rates of acute grade >=2 GI toxicity were also significantly lower with MRI-guidance (0.0% in the MRI group vs. 10.5% in the CT group). On multivariable analysis, which controls for differences in the use of hydrogel spacer, prostate size, and baseline urinary symptoms, the MRI- guidance arm was associated with a 60% reduction in odds of grade >=2 GU toxicity. Perhaps even more notably, there were improvements in multiple patient-reported outcomes. Significantly more patients receiving CT-guided SBRT experienced large increases in urinary symptoms, as measured by a >15 points increase in International Prostate Symptom Score (IPSS) (6.8% in the MRI group vs. 19.4% in the CT group). Similarly, a significantly greater percentage of patients experienced a clinically notable decrease in bowel-related quality of life with CT-guided, as measured by the Expanded Prostate Cancer Index Composite-26 (EPIC-26) survey (25.0% in the MRI group vs. 50.0% in the CT group). Finally, though it is too early to draw final conclusions as more than 2/3rds of men on the trial received hormonal therapy, exploratory analysis in men who did not receive hormonal therapy showed that patient- reported, sexual-function scores (by EPIC-26) decreased more in men receiving CT-guided SBRT. Announcement • Oct 25
ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients ViewRay, Inc. announced that the findings from the first Phase II prospective international multi-institutional study to deliver ablative doses of radiation to pancreatic cancer patients will be presented at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO), being held October 23-26, 2022, at the Henry B. Gonzalez Convention Center in San Antonio. The results will be featured as part of the Special Session of Late-Breaking Abstracts and will take place on Tuesday, October 25, at 3:00 p.m. Central Time. The data will be presented by Parag Parikh, M.D., study's principal investigator and Director of GI Radiation Oncology and MR-Guided Radiation Therapy at the Henry Ford Cancer Institute in Detroit. The trial, titled "Stereotactic MRI-Guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer" -- and known as SMART Pancreas (NCT 03621644) -- was launched in 2019 in response to compelling retrospective data that suggested the potential for ablative dose radiation to improve overall survival relative to patients receiving lower radiation doses without increasing the rate of severe gastrointestinal toxicity. In the SMART Pancreas study, 136 patients were treated at 13 international centers with ablative MRIdian SMART, 50Gy over 5 fractions. The study's primary outcome measured grade 3 or higher gastrointestinal toxicity in the first 90 days after treatment. The study's primary safety objective was met, with zero incidences of acute grade 3+ GI toxicity definitely-related to SMART treatment. Secondary measures of the study include overall survival, local control, distant progression-free survival, and changes in patient-reported quality of life. While study patients are still early in the follow-up period, 16.4 months from diagnosis and 8.8 months from SMART treatment, the ASTRO presentation will highlight preliminary clinical outcomes data of 1-year local control and distant progression-free survival were 82.9% and 50.6% respectively. One-year overall survival from diagnosis was 93.9%. Announcement • Oct 19
ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy ViewRay, Inc. announced the launch of a phase III randomized controlled trial titled "Locally Advanced Pancreatic cancer treated with ABLAtivE stereotactic MRI-guided adaptive radiation therapy" -- also known as LAP-ABLATE. LAP-ABLATE will compare stand-alone multi-agent chemotherapy, which is the current standard of care for patients with locally advanced pancreatic cancer, to patients receiving a combination of chemotherapy and 5-fraction MRIdian SMART (stereotactic MR-guided adaptive radiotherapy). The study is designed to demonstrate superior overall survival in patients receiving post-chemotherapy MRIdian SMART. The anticipated enrollment target is 267 patients (NCT05585554). Although surgery is considered a potentially curative treatment for non-metastatic pancreatic cancer, less than 20% of patients are candidates. Of the remaining patients, approximately 40% have locally advanced pancreatic cancer (LAPC), and another 40% have distant metastases at diagnosis. LAPC is usually not resectable because the tumor encases major abdominal blood vessels. Further studies have supported the notion that significantly escalating the radiation dose to an ablative range may improve overall survival. But the feasibility of delivering ablative radiation dose to the pancreas has historically been limited. Previous clinical trials have resulted in a high risk of injury to the stomach and nearby bowel loops, resulting in severe side effects such as pain, bleeding, or obstruction. Announcement • Oct 15
ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022 ViewRay, Inc. announced that they will report Q3, 2022 results After-Market on Nov 01, 2022 Announcement • Sep 08
ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients ViewRay, Inc. announced that the company's MRIdian MRI- Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China. This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART), allowing treatment that integrates diagnostic-quality MR imaging, on-table adaptive replanning, and continuous, real-time, soft tissue tracking and automated beam gating. Recognizing the need to improve both social and economic development, China has put health at the core of policy making. Healthy China 2030 lays out China's long-term approach to healthcare and shows its commitment to improving healthcare services across the country.(1) There are about 4.6 million new cases of cancer diagnosed annually in China.(2) The Healthy China 2030 initiative aims to increase the five-year survival rate of cancer patients by 15%. The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy. To date, nearly 25,000 patients have been treated with MRIdian. Currently, 53 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. Announcement • Aug 09
ViewRay, Inc. Selects Denver for Headquarters ViewRay, Inc. announced that it is moving its headquarters to Denver, Colorado as it continues to attract top-tier talent from the state's growing medical technology sector. In mid-2019, ViewRay established an office in Denver starting with fewer than ten teammates. ViewRay's presence in Denver has now grown to over 50 teammates with the expansion of the company's international marketing, finance, and legal teams. ViewRay is one of the fastest growing companies in the med-tech sector with plans for considerable growth in Denver. ViewRay expects to continue expanding its Denver team with additional high-paying roles in product development, manufacturing, and quality and, in 2023, the company plans to add another building focused on development, manufacturing, and physician training. Reported Earnings • Aug 03
Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.19 loss in 2Q 2021) Second quarter 2022 results: US$0.15 loss per share (up from US$0.19 loss in 2Q 2021). Revenue: US$22.1m (up 47% from 2Q 2021). Net loss: US$27.6m (loss narrowed 11% from 2Q 2021). Over the next year, revenue is forecast to grow 46%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Aug 03
Viewray, Inc. Updates Earnings Guidance for the Year 2022 ViewRay, Inc. updated earnings guidance for the year 2022. The company updated its 2022 guidance of total revenue by raising the bottom end of the range from $84 million to $90 million, while reiterating the top end of the range of $104 million. Announcement • Jul 20
ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022 ViewRay, Inc. announced that they will report Q2, 2022 results After-Market on Aug 02, 2022 Recent Insider Transactions • May 13
President recently bought €379k worth of stock On the 11th of May, Scott Drake bought around 157k shares on-market at roughly €2.42 per share. This was the largest purchase by an insider in the last 3 months. Scott has been a buyer over the last 12 months, purchasing a net total of €821k worth in shares. Reported Earnings • May 07
First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.17 loss in 1Q 2021) First quarter 2022 results: US$0.14 loss per share (up from US$0.17 loss in 1Q 2021). Revenue: US$18.9m (up 22% from 1Q 2021). Net loss: US$25.8m (loss narrowed 3.6% from 1Q 2021). Over the next year, revenue is forecast to grow 45%, compared to a 7.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings. Announcement • May 06
ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022 ViewRay, Inc. reiterated earnings guidance for the year 2022. The company reiterated its 2022 guidance of total revenue in the range of $84 million to $104 million. Announcement • May 02
ViewRay, Inc., Annual General Meeting, Jun 10, 2022 ViewRay, Inc., Annual General Meeting, Jun 10, 2022, at 08:30 Pacific Standard Time. Agenda: To elect the three Class I directors named in the Proxy Statement to hold office until the annual meeting of stockholders to be held in 2024 and until their successors are duly elected and qualified; to approve an amendment to our Amended and Restated 2015 Equity Incentive Award Plan in order to increase the number of shares available for issuance under the 2015 Plan; to ratify the selection, by the audit committee and our board of directors, of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; to conduct an advisory vote to approve ViewRay’s 2021 executive compensation; and to consider other matter. Announcement • Apr 22
ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022 ViewRay, Inc. announced that they will report Q1, 2022 results on May 05, 2022 Recent Insider Transactions • Mar 15
Insider recently bought €88k worth of stock On the 11th of March, Susan Schnabel bought around 25k shares on-market at roughly €3.52 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €799k more in shares than they have sold in the last 12 months. Reported Earnings • Feb 26
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: US$0.67 loss per share (up from US$0.73 loss in FY 2020). Revenue: US$70.1m (up 23% from FY 2020). Net loss: US$110.0m (loss widened 2.0% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 36%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Feb 25
Viewray, Inc. Provides Revenue Guidance for the Year 2022 ViewRay, Inc. provided revenue guidance for the year 2022. For the year, the company total revenue to be in the range of $84 million to $104 million. Announcement • Feb 16
ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer ViewRay, Inc. announced that interim data from the single center Phase III randomized MIRAGE trial, led by UCLA, comparing MRIdian MRI-guided vs. CT-guided SBRT for localized prostate cancer, will be featured at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, held February 17-19 in San Francisco. Interim analysis of the primary endpoint signaled superiority of MRIdian MRI-guided SBRT with a significant reduction in acute grade =2 GU toxicity in men receiving MRI-guided SBRT over those receiving CT-guided SBRT. The interim analysis of data from 100 patients eligible for evaluation (51 in the CT group and 49 in the MRI group) showed a statistically significant reduction in acute grade =2 GU toxicity in men receiving MRI-guided SBRT (47.1% in the CT group vs. 22.4% in the MRI group) and a significant reduction in acute grade =2 gastrointestinal (GI) toxicity in men receiving MRI-guided SBRT (13.7% in the CT group vs. 0% in the MRI group). Acute grade =2 GU toxicity can include adverse events range from frequent, urgent, or painful urination to pelvis pain, bladder spasms, or blood in the urine. Acute grade =2 GI toxicity can include adverse events ranging from diarrhea, discharge, or rectal/abdominal pain to abdominal distention or obstruction. Patient-reported outcomes were measured using the International Prostate Symptom Score (I-PSS) and Expanded Prostate cancer Index Composite (EPIC-26). Patient reported urinary and bowel function metrics were better preserved at the 1-month time point with MRI-guidance, though this difference dissipates at the 3-month time point, potentially due to management of side effects. Announcement • Feb 11
ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022 ViewRay, Inc. announced that they will report Q4, 2021 results After-Market on Feb 24, 2022 Recent Insider Transactions • Nov 20
Chief Financial Officer recently bought €88k worth of stock On the 19th of November, Zachary Stassen bought around 18k shares on-market at roughly €4.95 per share. In the last 3 months, they made an even bigger purchase worth €181k. Zachary has been a buyer over the last 12 months, purchasing a net total of €269k worth in shares. Recent Insider Transactions • Aug 26
Chief Financial Officer recently bought €181k worth of stock On the 24th of August, Zachary Stassen bought around 40k shares on-market at roughly €4.53 per share. This was the largest purchase by an insider in the last 3 months. This was Zachary's only on-market trade for the last 12 months. Reported Earnings • Aug 08
Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020) The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: US$15.0m (up 5.7% from 2Q 2020). Net loss: US$31.0m (loss widened 18% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • May 08
ViewRay, Inc. Not to Provide Financial Guidance Due to the ongoing impact and uncertainty of the COVID-19 pandemic globally, ViewRay, Inc. will not be providing financial guidance at this time. Reported Earnings • May 08
First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$15.5m (up 8.9% from 1Q 2020). Net loss: US$26.7m (loss narrowed 2.9% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Executive Departure • Apr 02
Chief Operating Officer has left the company On the 31st of March, Shahriar Matin's tenure as Chief Operating Officer ended after 2.7 years in the role. As of December 2020, Shahriar personally held 434.19k shares (€1.4m worth at the time). A total of 2 executives have left over the last 12 months. Announcement • Mar 16
ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021 On March 15, 2021, ViewRay, Inc. announced the resignation of Shahriar Matin, Chief Operating Officer of the Company, effective March 31, 2021. Reported Earnings • Mar 05
Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019) The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$57.0m (down 35% from FY 2019). Net loss: US$107.9m (loss narrowed 10% from FY 2019). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Mar 05
Revenue beats expectations Revenue exceeded analyst estimates by 0.8%. Over the next year, revenue is forecast to grow 26%, compared to a 13% growth forecast for the Medical Equipment industry in Germany. Announcement • Feb 20
ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021 ViewRay, Inc. announced that they will report Q4, 2020 results After-Market on Mar 04, 2021 Executive Departure • Feb 16
Independent Director has left the company On the 9th of February, D. Grossman's tenure as Independent Director ended after 2.6 years in the role. As of December 2020, Grossman personally held 31.38k shares (€98k worth at the time). A total of 2 executives have left over the last 12 months. Announcement • Feb 13
ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors ViewRay, Inc. announced that D. Keith Grossman has retired from its Board of Directors, effective February 9, 2021. Announcement • Feb 12
Viewray, Inc. Appoints Phil Spencer to Its Board of Directors ViewRay, Inc. announced the appointment of Phil Spencer to its Board of Directors, effective February 9, 2021. Mr. Spencer has a long track record of delivering substantial financial value as a CEO and board member over the last 20 years. He is currently the President and CEO of Mega-Broadband Investments (MBI). MBI recently acquired Northland Communications, Eagle Communications, Vyve Broadband, and FamilyView Cable, and currently passes 650,000 homes & businesses in fifteen states. Prior to MBI, Phil was Chief Executive Officer of NewWave Communications which was acquired by CableOne. He previously held numerous other CEO and Board of Director roles. Announcement • Feb 05
Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac ViewRay, Inc. announced that Edogawa Hospital in Tokyo is the first hospital in Japan to treat patients with the MRIdian Linac System. Edogawa Hospital began treating patients in 2018 on the MRIdian cobalt system. The upgrade to MRIdian Linac combines MRI-guidance with a linear accelerator for faster and more accurate delivery of radiation therapy. Unlike conventional radiation therapy systems, MRIdian combines MR imaging and radiation therapy in one system. This combination allows physicians to define treatment margins based on MR images of patient anatomy in support of the delivery of safe and effective radiotherapy -- including stereotactic body radiation therapy (SBRT), which utilizes ablative, high-doses in five or fewer treatment sessions. MRIdian enables continuous tracking of the target and surrounding soft tissues without fiducial markers, adaptation of therapy in response to daily anatomical changes, and automatic pausing of the radiation (beam gating) if the target moves outside of the user-defined boundary. This allows for delivery of the prescribed dose to the target while sparing surrounding healthy tissue and critical structures, potentially minimizing toxicities typically associated with radiation therapy. Announcement • Jan 28
The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac ViewRay, Inc. announced that Henry Ford Cancer Institute has installed its second MRIdian Linac at its new cancer pavilion, Henry Ford Cancer Institute – Detroit, which began offering patient care on January 20, 2021. Following FDA-clearance of the MRIdian Linac in February 2017, Henry Ford Cancer Institute became the first center in the world to install the next-generation system at one of its sites in Grosse Pointe Farms, Michigan. The MRIdian Linac was the first commercially available device to combine MRI-guidance with linear accelerator radiation delivery. The Henry Ford Cancer Institute team has been leading the novel Stereotactic MR-guided Adaptive Radiation Therapy (SMART) trial [NCT03621644], a multi-institutional prospective, phase II study evaluating MRIdian outcomes in the treatment of pancreatic cancer. They also became the first center to use an MRI Linac to treat 100 pancreatic cancer and 100 liver cancer patients in the world. Of particular interest to clinicians are the MRIdian Linac system's on-table adaptive capabilities, which include the ability to reshape the radiation to match changes in the patient's anatomy between treatments. MRIdian integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue and tumors while radiation is delivered. These capabilities allow MRIdian to deliver accurate doses of radiation to the tumor while protecting nearby healthy tissues and vulnerable structures, enabling personalized, non-invasive cancer treatment. The use of MRIdian is associated with improved patient outcomes, shorter treatment durations, and reduced treatment-related side effects. Announcement • Jan 22
An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million. An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million on January 22, 2021. Under the terms of the deal, Elekta sold 11.5 million shares. Elekta has no remaining shares in ViewRay after the transaction.
An unknown buyer completed the acquisition of 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) on January 22, 2021. Announcement • Jan 05
ViewRay, Inc. has completed a Follow-on Equity Offering in the amount of $50.0035 million. ViewRay, Inc. has completed a Follow-on Equity Offering in the amount of $50.0035 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,310,000
Price\Range: $4.85 Is New 90 Day High Low • Jan 05
New 90-day high: €4.22 The company is up 59% from its price of €2.66 on 07 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Dec 11
New 90-day high: €3.68 The company is up 48% from its price of €2.48 on 11 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 14
New 90-day high: €3.26 The company is up 18% from its price of €2.76 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Recent Insider Transactions • Nov 14
President recently bought €423k worth of stock On the 10th of November, Scott Drake bought around 155k shares on-market at roughly €2.73 per share. This was the largest purchase by an insider in the last 3 months. This was Scott's only on-market trade for the last 12 months. Announcement • Nov 11
Universitair Ziekenhuis Brussels Purchases ViewRay's MRIdian Linac ViewRay, Inc. announced that Universitair Ziekenhuis Brussels has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radiation therapy device that combines the latest innovations in precision radiation delivery and ground-breaking MR-guidance. Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. Together with other technical innovations, this offers advantages for the delivery of safe and effective radiotherapy, including the ability to see the tumor and surrounding tissue during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments, continuous tracking of the tumor during treatment, and automatic pausing of the radiation if the tumor moves outside of the boundary. As a result, the system delivers ablative, high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage. Unlike conventional radiation therapy systems, MRIdian combines an MRI system with a radiation therapy system. Together with other technical innovations, this offers advantages for the delivery of safe and effective radiotherapy, including the ability to see the tumor and surrounding tissue during treatment, adaptation of the therapy in response to changes in patient anatomy and tumor size between treatments, continuous tracking of the tumor during treatment, and automatic pausing of the radiation if the tumor moves outside of the boundary. As a result, the system delivers ablative, high-dose radiation to the tumor while protecting the surrounding healthy tissue from damage. Reported Earnings • Nov 07
Third quarter 2020 earnings released: US$0.19 loss per share The company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$10.1m (down 52% from 3Q 2019). Net loss: US$28.1m (loss widened 35% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue beats expectations Revenue exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 30%, compared to a 13% growth forecast for the Medical Equipment industry in Germany. Announcement • Oct 16
ViewRay, Inc. to Report Q3, 2020 Results on Nov 05, 2020 ViewRay, Inc. announced that they will report Q3, 2020 results at 5:00 PM, Eastern Standard Time on Nov 05, 2020 Announcement • Jul 17
ViewRay, Inc. to Report Q2, 2020 Results on Jul 30, 2020 ViewRay, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Jul 30, 2020 